Senhwa Biosciences, Inc.

Penn State College of Medicine, Beat Childhood Cancer Research Consortium, Four Diamonds, and Senhwa Biosciences launch a clinical trial evaluating the investigational drug silmitasertib in combination with FDA-approved drugs for solid tumors in children and young adults, focusing on neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma. The trial aims to establish a recommended dose, assess safety, tolerability, and efficacy, and enroll up to 114 participants nationwide. Funding is provided by the Beat Childhood Cancer Foundation and the Little Warrior Foundation.

Penn State College of Medicine, Beat Childhood Cancer Research Consortium, and Four Diamonds launch a clinical trial to evaluate silmitasertib in combination with FDA-approved drugs for solid tumors in children and young adults, focusing on neuroblastoma, Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and liposarcoma.